? CORE A The administrative core for Center for Precision Medicine in Leukemia is co-led by the Co-principal investigators for this P50, Drs. Relling and Loh. The executive committee also includes Dr. Evans, Dr. Hunger, and Dr. Cheng. This is an interdisciplinary group of experienced basic, translational, and clinical investigators who have a proven track record of working together and meeting deadlines. They will work together to oversee the progress on all three projects and two cores to ensure that the Center?s milestones are set and met, and to facilitate interactions between the Center and external groups. The PI and Co-PI (Relling and Loh) are supported by administrative staff at SJCRH. The P50 Administrator, Dawn Bowen, has considerable experience in cancer center and grants administration.
The Specific Aims of this essential core are: (1) To oversee, monitor, and prioritize internal progress of projects, cores and programs to ensure the Center is meetings its milestones. (2) To facilitate internal interactions among Center projects and cores. (3) To facilitate external outreach of the Center to the Pharmacogenomics Research Network (PGRN), the genomics community, the pediatric and adult ALL cooperative groups and other ALL clinical consortia, and the external genomics groups performing clinical implementation of pharmacogenomics and precision medicine. (4) To execute changes in emphasis and direction and devise contingency plans based on changing priorities over time. (5) To ensure outreach to, appointment of, interface with, response to, and planning of meetings with the External Advisory Board (EAB). (6) To coordinate Executive Committee conference calls, monthly web-based Center Work in Progress seminars, EAB interactions, and the annual Center Retreat. (7) To take a leadership role in the PGRN and program and organize a meeting of the PGRN. (8)To ensure timely data sharing and data deposits. (9) To manage budgetary issues and prepare progress reports.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Specialized Center (P50)
Project #
1P50GM115279-01
Application #
8933499
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Li, Jian-Feng; Dai, Yu-Ting; Lilljebjörn, Henrik et al. (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115:E11711-E11720
Heikamp, Emily B; Pui, Ching-Hon (2018) Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr 203:14-24.e2
Roberts, Kathryn G; Reshmi, Shalini C; Harvey, Richard C et al. (2018) Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. Blood 132:815-824
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Goetz, Matthew P; Sangkuhl, Katrin; Guchelaar, Henk-Jan et al. (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther 103:770-777
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Nishii, Rina; Moriyama, Takaya; Janke, Laura J et al. (2018) Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood 131:2466-2474
Pui, Ching-Hon; Liu, Yiwei; Relling, Mary V (2018) How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer 65:
Zhang, Yingchi; Gao, Yufeng; Zhang, Hui et al. (2018) PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood 131:2256-2261
Gupta, Sumit; Devidas, Meenakshi; Loh, Mignon L et al. (2018) Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia 32:1370-1379

Showing the most recent 10 out of 72 publications